Evaluating the efficacy and safety of letermovir compared to valganciclovir for the prevention of human cytomegalovirus disease in adult lung transplant recipients.

Sydni Martinez Devika SinduMichael D NailorLauren Cherrier Sofya Tokman Rajat Walia Kellie J Goodlet

Published in: Transplant infectious disease : an official journal of the Transplantation Society (2024)

LET prophylaxis was associated with a low rate of CMV reactivation and leukopenia recovery. LET may represent a reasonable prophylaxis option for lung transplant recipients unable to tolerate VGCV.

Keyphrases

endothelial cells
pluripotent stem cells
young adults
childhood cancer
diffuse large b cell lymphoma